PharmSource-Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars-2018 Edition
The report provides an extensive research and detailed analysis of the present market along with future outlook.
(EMAILWIRE.COM, January 08, 2019 ) Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large molecule, immunogenic drugs produced from living cells. Innovator biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.
There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.
Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.
More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2435941
Key Questions Answered
- What biosimilars are marketed in the US and EU?
- How is biosimilar manufacturing and packaging outsourced?
- What therapies are in the biosimilar pipeline?
- In what regions is biosimilar development concentrated?
- How does biosimilar manufacturing differ by molecule type?
- When will innovator biologic patents expire, allowing biosimilar development?
- What proportion of biosimilar manufacturing is kept in-house?
- How will contract analytical testing services be affected by the rise of biosimilars?
Scope:
Detailed view of -
- Marketed Innovator Biologics.
- Marketed Biosimilars.
- Innovator Biologic Patent Expiries and Waves of Biosimilar Opportunity.
- Biosimilar Clinical Pipeline.
- Existing CDMO Contracts for Biosimilars for API, Dose and Packaging.
Reasons to buy:
- This 74-page report gives important, expert insight you wont find in any other source. 20 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the biosimilar marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and Biotech companies involved in the development of innovator biologics or biosimilars.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2435941
Key Players:
AbbVie
Accord Healthcare
Advanced Accelerator Applications
Aeterna Zentaris
Aetos Biologics
Alexion Pharmaceuticals
Allpack
AlphaMab
Amgen
APEIRON Biologics
Apotex
Aptevo Therapeutics
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Beijing Fogangren Bio-Pharm Tech
Biogen
BioMarin Pharmaceutical
BioReliance
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Catalent
Celgene
Celltrion
Chiesi Farmaceutici
Chugai Pharmaceutical Co
Clinuvel Pharmaceuticals
Coherus BioSciences
Cook Pharmica
CSL
Dompe Farmaceutici
Eli Lilly
Elusys Therapeutics
Emergent BioSolutions
Endo International
F. Hoffmann-La Roche
Ferring International Center
Finox Biotech
GE Healthcare
Gedeon Richter
Gene Techno Science
Genentech
Genor BioPharma
GlaxoSmithKline
Grunenthal Group
Horizon Pharma
IDT Biologika
Intas Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Jazz Pharmaceuticals
Johnson & Johnson
KBI Biopharma
Kyowa Hakko Kirin
La Jolla Pharmaceutical Company
LG Chem
MabPlex International
MannKind Corp
Medac
Medice Arzneimittel Pόtter & Co.
MedImmune
Merck & Co / MSD
Merck KGaA
Mustafa Nevzat Pharmaceuticals
Mylan
Novartis
Novartis International
Novelion Therapeutics
Novo Nordisk AS
Octapharma
Ono Pharmaceutical Co
Pall Corp
Patheon
PCI Pharma Services
Pfizer
Pharming Group
Polymun Scientific Immunbiologische Forschung
Portola Pharmaceuticals
Protalix BioTherapeutics
Regeneron Pharmaceuticals
Rentschler Biopharma
rEVO Biologics
Richter Gedeon
Richter-Helm Biologics & Co.
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
ScinoPharm Taiwan
Continued
Key Points from TOC:
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
8. Notes on Methodology 56
9. Appendix 57
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/pharmsource-catching-the-next-wave-how-much-have-cmos-benefited-from-biosimilars-2018-edition
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.
Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.
More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2435941
Key Questions Answered
- What biosimilars are marketed in the US and EU?
- How is biosimilar manufacturing and packaging outsourced?
- What therapies are in the biosimilar pipeline?
- In what regions is biosimilar development concentrated?
- How does biosimilar manufacturing differ by molecule type?
- When will innovator biologic patents expire, allowing biosimilar development?
- What proportion of biosimilar manufacturing is kept in-house?
- How will contract analytical testing services be affected by the rise of biosimilars?
Scope:
Detailed view of -
- Marketed Innovator Biologics.
- Marketed Biosimilars.
- Innovator Biologic Patent Expiries and Waves of Biosimilar Opportunity.
- Biosimilar Clinical Pipeline.
- Existing CDMO Contracts for Biosimilars for API, Dose and Packaging.
Reasons to buy:
- This 74-page report gives important, expert insight you wont find in any other source. 20 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the biosimilar marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and Biotech companies involved in the development of innovator biologics or biosimilars.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2435941
Key Players:
AbbVie
Accord Healthcare
Advanced Accelerator Applications
Aeterna Zentaris
Aetos Biologics
Alexion Pharmaceuticals
Allpack
AlphaMab
Amgen
APEIRON Biologics
Apotex
Aptevo Therapeutics
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Beijing Fogangren Bio-Pharm Tech
Biogen
BioMarin Pharmaceutical
BioReliance
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Catalent
Celgene
Celltrion
Chiesi Farmaceutici
Chugai Pharmaceutical Co
Clinuvel Pharmaceuticals
Coherus BioSciences
Cook Pharmica
CSL
Dompe Farmaceutici
Eli Lilly
Elusys Therapeutics
Emergent BioSolutions
Endo International
F. Hoffmann-La Roche
Ferring International Center
Finox Biotech
GE Healthcare
Gedeon Richter
Gene Techno Science
Genentech
Genor BioPharma
GlaxoSmithKline
Grunenthal Group
Horizon Pharma
IDT Biologika
Intas Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Jazz Pharmaceuticals
Johnson & Johnson
KBI Biopharma
Kyowa Hakko Kirin
La Jolla Pharmaceutical Company
LG Chem
MabPlex International
MannKind Corp
Medac
Medice Arzneimittel Pόtter & Co.
MedImmune
Merck & Co / MSD
Merck KGaA
Mustafa Nevzat Pharmaceuticals
Mylan
Novartis
Novartis International
Novelion Therapeutics
Novo Nordisk AS
Octapharma
Ono Pharmaceutical Co
Pall Corp
Patheon
PCI Pharma Services
Pfizer
Pharming Group
Polymun Scientific Immunbiologische Forschung
Portola Pharmaceuticals
Protalix BioTherapeutics
Regeneron Pharmaceuticals
Rentschler Biopharma
rEVO Biologics
Richter Gedeon
Richter-Helm Biologics & Co.
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
ScinoPharm Taiwan
Continued
Key Points from TOC:
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
8. Notes on Methodology 56
9. Appendix 57
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/pharmsource-catching-the-next-wave-how-much-have-cmos-benefited-from-biosimilars-2018-edition
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results